A High Risk/High Reward Way To Play The Shift To Biotech Solutions
When it comes to treating diseases, the author of today’s article notes “It seems that there is a shift away from treating symptoms with chemical…
Zenect Wealth
A New Multi-Bagger Opportunity In The Electric Vehicle Space
For those who missed out on the massive rallies of Tesla and other electric vehicle companies, today’s article highlights another potential multi-bagger opportunity in the…
The Approval Of An Oregon Ballot Measure Could Make This Biotech Startup An Under-The-Radar Election Winner
Amid all the high drama surrounding last week’s elections, a smaller development could have big implications for one biotech startup. As today’s article explains, voters…
More Outperformance Ahead For These 2 “Class of 2018” Biotech Stocks?
The two biotech stocks highlighted in today’s article both made their public market debuts in 2018 – and both have performed very well for investors…
These 5 Drug/Biotech Stocks Have The Combination To Unlock An Earnings Surprise
Amid a third-quarter earnings season that has been a mixed bag of beats and misses for drug/biotech companies, today’s article highlights five drug/biotech stocks that…
These 3 Biotechs Have Different Approaches To A COVID-19 Vaccine, But The Same Analyst Rating: ‘Buy’
An intranasal vaccine, an mRNA vaccine, and a T-cell activation vaccine: the three biotech companies discussed in today’s article are approaching the virus that causes…
This Biotech Stock Could Be A Good “Bad News Buy”
When it comes to the biotech stock that’s the focus of today’s article, which plummeted in mid-October when the company abruptly pulled the plug on…
These Biotechs Are Awaiting FDA Rulings In November
October has seen the FDA approve the first drug for COVID-19 (remdesivir), the first treatment for Ebola virus (Regeneron Pharmaceuticals’ Inmazeb), and the first drug…
Consider Excising These “Unhealthy” Biotech Stocks From Your Portfolio
When it comes to the seven “unhealthy” biotech stocks that are the focus of today’s article, the author advises the following: “While these aren’t terrible…
Is The Stage Being Set For A Strong Biotech Rally?
Amid setbacks for various potential COVID-19 vaccines and treatments, election risk, strengthening M&A activity, and more, what’s the outlook for healthcare and biotech in the…